Stockscreener 앱 받기
12.86
0.16%
0.02
전일 마감가:
$12.84
열려 있는:
$13.05
하루 거래량:
8.68M
Relative Volume:
1.01
시가총액:
$14.81B
수익:
$14.33B
순이익/손실:
$-3.79B
주가수익비율:
-4.0568
EPS:
-3.17
순현금흐름:
$1.84B
1주 성능:
+0.78%
1개월 성능:
+12.22%
6개월 성능:
+41.63%
1년 성능:
+13.40%
1일 변동 폭
$12.73
$13.08
1주일 범위
$12.53
$13.49
52주 변동 폭
$6.85
$13.49
비아트리스 Stock (VTRS) Company Profile
명칭
Viatris Inc
전화
(724) 514-1465
주소
1000 MYLAN BOULEVARD, CANONSBURG
VTRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
12.86 | 14.79B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
124.65 | 55.21B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.16 | 51.59B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.83 | 43.51B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.76 | 37.11B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
464.93 | 20.32B | 3.08B | 1.24B | 1.07B | 25.61 |
비아트리스 Stock (VTRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-06-06 | 개시 | Goldman | Neutral |
| 2024-07-19 | 재개 | Jefferies | Buy |
| 2023-10-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-06-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2023-04-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-02-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-10 | 업그레이드 | UBS | Sell → Neutral |
| 2022-11-08 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 재개 | Jefferies | Hold |
| 2022-06-14 | 개시 | UBS | Sell |
| 2022-05-10 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 개시 | Citigroup | Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 개시 | Argus | Hold |
| 2020-12-14 | 개시 | Bernstein | Mkt Perform |
모두보기
비아트리스 주식(VTRS)의 최신 뉴스
Levels Update: Will Viatris Inc stock hit new highs in YEARJuly 2025 Spike Watch & Precise Buy Zone Identification - baoquankhu1.vn
Argus Research Upgrades Viatris (VTRS) - Nasdaq
Biocon Secures Rs 4,150 Cr Through QIP to Buy Out Viatris Stake in Biologics Arm - Medical Dialogues
Viatris stock tests multi-year ceiling after impressive rally - FXStreet
United States Treatment-Resistant Depression Market to grow - openPR.com
Cash offers target up to $450M of Viatris 2026 and 2025 notes - Stock Titan
Viatris (VTRS) Gets a Sell from Bank of America Securities - The Globe and Mail
Biocon Raises Rs 4,150 Cr via QIP Issue - Rediff MoneyWiz
RSI Check: Is Viatris Inc. impacted by rising ratesWeekly Profit Summary & Daily Profit Focused Screening - baoquankhu1.vn
Viatris Inc. (NASDAQ: VTRS): Navigating the Pivot from Integration to Innovation - FinancialContent
Viatris stock steadies in premarket after a 5% jump on JPM conference remarks — what investors watch next - TechStock²
Generic Drugs Market to Hit US$ 942.69 Billion by 2033 | CAGR 7.1% | - openPR.com
Viatris Inc. stock rises Tuesday, outperforms market - MSN
Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight - GlobeNewswire Inc.
What is the earnings history of Viatris IncWeekly Investment Recap & Growth Oriented Trade Recommendations - baoquankhu1.vn
Viatris Stock: Is Wall Street Bullish or Bearish? - MSN
Viatris hits main goals in Phase 3 trial for birth control patch - MSN
Mylan, Aurobindo Must Face Generic Drug Price-Fixing Claims - Law360
Viatris Inc. Stock Rises Friday, Outperforms Market - 富途牛牛
Why Analysts See The Viatris (VTRS) Story Shifting With Affordable Medicines And A US$16 Target - Yahoo Finance
Viatris Inc.: Can a Hybrid Pharma Powerhouse Reinvent the Generic Drug Game? - AD HOC NEWS
Goldman Sachs Adjusts Price Target on Viatris to $13 From $12, Maintains Neutral Rating - marketscreener.com
Can Viatris Inc. stock deliver strong Q4 earningsTrend Reversal & Growth Focused Entry Point Reports - ulpravda.ru
How analysts revise price targets for Viatris Inc. (VIA) stockCPI Data & High Conviction Investment Ideas - ulpravda.ru
Does Viatris Inc. (VIA) stock trade below intrinsic value2025 Historical Comparison & Real-Time Volume Trigger Notifications - ulpravda.ru
Viatris Inc. Stock Rises Thursday, Outperforms Market - 富途牛牛
Performance Recap: Why Viatris Inc. stock remains on buy listsMarket Activity Report & Safe Entry Zone Identification - ulpravda.ru
Viatris names veteran executive to lead people and corporate affairs - The Business Journals
Viatris stock hits 52-week high at 12.68 USD By Investing.com - Investing.com South Africa
Viatris stock hits 52-week high at 12.68 USD - Investing.com
Why Viatris Inc. stock remains on buy listsEarnings Trend Report & AI Powered Trade Plan Recommendations - ulpravda.ru
Viatris appoints Lara Ramsburg as chief people and corporate affairs officer - marketscreener.com
Viatris names Lara Ramsburg as chief people and corporate affairs officer - Investing.com Australia
Viatris names Lara Ramsburg as chief people and corporate affairs officer By Investing.com - Investing.com South Africa
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer - Viatris
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer – Company Announcement - Financial Times
Viatris Inc.: How a Quiet Generic Drug Giant Is Re?wiring Global Healthcare - AD HOC NEWS
Barclays initiates Viatris (VTRS) with overweight as pharma sentiment improves - MSN
Is Viatris stock outperforming the Dow? - MSN
Viatris (VTRS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Taxanes Market to Reach US$ 8.67 Billion by 2032 at 10.73% CAGR; - openPR.com
1 Healthcare Stock to Target This Week and 2 We Turn Down - FinancialContent
A Look At Viatris (VTRS) Valuation After Recent Regulatory And Pipeline Milestones - Yahoo Finance
Anti-Depression Drugs Market to Reach USD 22.10 Billion by 2031 | - openPR.com
Viatris Inc.: Can a Hybrid Pharma Powerhouse Redefine Global Generics and Biosimilars? - AD HOC NEWS
Take Profit: Will Viatris Inc stock outperform Nasdaq indexJuly 2025 Setups & Verified Chart Pattern Signals - moha.gov.vn
Viatris Inc. (VTRS) Provides Updates on Four Recent Regulatory Milestones - Finviz
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
Viatris stock hits 52-week high at $12.60 By Investing.com - Investing.com Nigeria
Viatris stock hits 52-week high at $12.60 - Investing.com India
Viatris Inc. stock rises Wednesday, outperforms market - MSN
비아트리스 (VTRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
8.75%
1.45%
자본화:
|
볼륨(24시간):